All CIRM Grants

Search Filters »

Institution Researcher name Grant Type Grant Title Award Value
Humacyte, Inc. Jeffrey Lawson Clinical Trial Stage Projects A Human Acellular Vessel in Patients Needing Renal Replacement Therapy: A Comparison with ePTFE Grafts as Conduits for Hemodialysis (HUMANITY) $7,625,000
Capricor, Inc Dr. Linda Marban Clinical Trial Stage Projects Allogeneic Cardiosphere-Derived Cells for Duchenne Muscular Dystrophy Cardiomyopathy $3,376,259
University of California, Davis Dr Mehrdad Abedi Clinical Trial Stage Projects Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-selected CD34+ Cells in AIDS lymphoma patients $8,414,265
ImmunoCellular Therapeutics Anthony J. Gringeri Clinical Trial Stage Projects A Phase III randomized double-blind, controlled study of ICT 107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy $5,391,016
Caladrius Biosciences Robert Dillman Clinical Trial Stage Projects Tumor stem cell-targeted immunotherapy for metastatic melanoma –a randomized phase 3 clinical trial. $3,000,000
University of California, Los Angeles Dr. Donald B. Kohn Clinical Trial Stage Projects A Phase I/II, Non Randomized, Multicenter, Open-Label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease $7,083,364
University of California, San Diego Mark H Tuszynski Late Stage Preclinical Projects Human Embryonic Stem Cell-Derived Neural Stem Cells for Severe Spinal Cord Injury (SCI) $6,000,000
Children’s Hospital of Los Angeles Shahab Asgharzadeh Late Stage Preclinical Projects Chimeric TGFB Signaling Receptor (CTSR) Enabled Anti-B7H3 CAR T-cell Therapy in Children and AYA with Recurrent Solid Tumors $5,954,784
University of California, San Francisco Thomas Martin Late Stage Preclinical Projects A 1XX-enhanced and fully non-viral BCMA CAR T cell therapy for Relapsed and Refractory Multiple Myeloma (UCCT-BCMA-1) $4,585,501
Elpida Therapeutics Mr. Terry Pirovolakis Late Stage Preclinical Projects Pre-Clinical To Clinical Gene Therapy Development For CMT4J $3,930,964
Cedars-Sinai Medical Center Dr. Eugenio Cingolani Late Stage Preclinical Projects Extracellular Vesicles for Ventricular Tachycardia $5,999,441
AcuraStem Inc. Mr. Samuel V. Alworth MS, MBA Late Stage Preclinical Projects Manufacturing of AS-202, an Antisense oligonucleotides for a Phase 1/2 Clinical Trial for Amyotrophic Lateral Sclerosis $0
City of Hope, Beckman Research Institute Prof. Karen S Aboody M.D. Late Stage Preclinical Projects Neural stem cell delivered CRAd-S-pk7 oncolytic viro-immunotherapy for ovarian cancer $5,314,547
Tr1X Inc. DR Maria Grazia Roncarolo Late Stage Preclinical Projects TRX103 for prevention of GvHD in patients receiving HLA mismatched related or unrelated allogeneic HSCT for the treatment of hematologic malignancies. $4,000,000
University of California, Irvine Kyriacos A Athanasiou Late Stage Preclinical Projects Treatment of the TMJ disc complex $6,000,000
Aspera Biomedicines, Inc. Catriona Jamieson Late Stage Preclinical Projects Cancer Stem Cell Interception with Rebecsinib: A First-in-Class ADAR1 Inhibitor $3,200,000
University of California, Los Angeles Dr. Jerome A. Zack Ph.D. Late Stage Preclinical Projects Clinical Translation of Autologous Regenerative Pluripotent Stem Cell Therapy for Blindness $6,000,000
Ryne Biotechnology Howard J Federoff Late Stage Preclinical Projects Allogeneic iPSC derived Dopaminergic Drug Product for Parkinson’s disease $4,000,000
Rampart Bioscience Jeffrey Bartlett Late Stage Preclinical Projects Ex vivo Engineering of Autologous Hematopoietic Stem Cells for the Treatment of Hypophosphatasia $3,999,980
Nammi Therapeutics, Inc. Dr. David R Stover Late Stage Preclinical Projects IND-Enabling activities for the masked immunocytokine, QXL138AM $3,999,113
Calidi Biotherapeutics, Inc. 8587949607 Boris Minev Late Stage Preclinical Projects Allogeneic mesenchymal stem cells loaded with oncolytic virus for cancer treatment $3,111,467
Ossium Health, Inc. Dr. Brian Johnstone Late Stage Preclinical Projects Development of OSSM-007, cryopreserved interferon-gamma primed allogeneic MSCs, for treatment of steroid refractory acute graft versus host disease $3,457,858
University of California, Davis Dr. Joseph S Anderson Late Stage Preclinical Projects Hematopoetic stem cell gene therapy for the treatment of Tay-Sachs disease $4,048,253
Stanford University Natalia Gomez-Ospina Late Stage Preclinical Projects Genome Editing of Autologous Hematopoietic Stem Cells to Treat Severe Mucopolysaccharidosis type 1 (Hurler Syndrome) $5,444,353
University of California, San Francisco Dr. Karin Lindgren Gaensler Late Stage Preclinical Projects Development of TriLeukeVax, an Engineered Autologous Leukemia Vaccine for Stimulating Cytolytic Immune Responses to Residual Leukemic Stem Cells $6,000,000
ImmunoVec Dr. Ryan L. Wong Late Stage Preclinical Projects Hematopoietic Stem Cell Gene Therapy for XCGD $3,999,959
University of California, Los Angeles Dr. Antoni Ribas M.D., Ph.D. Late Stage Preclinical Projects Skin regeneration and wound healing with a topical BRAF inhibitor $5,005,126
University of Southern California Frank Petrigliano Late Stage Preclinical Projects Plurocart: a novel stem cell-based implant for articular cartilage restoration $5,999,782
University of California, San Diego Thomas J Kipps Late Stage Preclinical Projects Late Stage Pre-Clinical Development of a Cirmtuzumab Based CAR T-cell for the Treatment of ROR1+ Hematological Malignancies $2,160,000
Stanford University Dr. Rosa Bacchetta Late Stage Preclinical Projects IND-enabling activities for a Phase 1 Study of Autologous CD4LVFOXP3 T Cells in Subjects with IPEX Syndrome $5,002,496
University of California, San Francisco Mark C. Walters M.D. Late Stage Preclinical Projects Curing Sickle cell Disease with CRISPR-Cas9 genome editing $2,242,805
University of California, Davis Dr. Diana L. Farmer Late Stage Preclinical Projects Placental Mesenchymal Stem Cell Augmentation of Fetal Myelomeningocele Repair $5,615,207
Ankasa Regenerative Therapeutics, Inc. Ying Zhu Late Stage Preclinical Projects IND-enabling development of ART352-L, an endogenous stem cell reactivation therapy to enhance bone healing in the elderly $3,987,693
City of Hope, Beckman Research Institute Xiuli Wang Late Stage Preclinical Projects CMV-specific T cells expressing anti-HIV CAR and CMV vaccine boost as immunotherapy for HIV/AIDS $3,812,797
University of California, San Francisco Dr. Krystof Bankiewicz Late Stage Preclinical Projects MRI Guided Delivery of Neural Progenitor Cells Secreting GDNF for the Treatment of Parkinson’s disease $5,757,078
Poseida Therapeutics, Inc. Devon J Shedlock Late Stage Preclinical Projects Late-Stage Preclinical Study of CAR-T Memory Stem Cells Targeting PSMA (P-PSMA-101) for the Treatment of Castrate-Resistant Metastatic Prostate Cancer $3,992,090
City of Hope, Beckman Research Institute Dr. Angelo Manuel Almeida Cardoso Ph.D., MD Late Stage Preclinical Projects Ex Vivo Gene Engineering of Blood Stem Cells for Enhanced Chemotherapy Efficacy in Glioblastoma Patients $3,684,259
University of California, Irvine Dr. Leslie M Thompson Late Stage Preclinical Projects An hESC-derived hNSC Therapeutic for Huntington’s Disease $5,635,393
Fate Therapeutics, Inc. Dr Bob Valamehr Late Stage Preclinical Projects IND enabling development of FT516: A Natural Killer Cell Immunotherapy for Cancer Derived from a Human Inducible Pluripotent Stem Cell $4,000,000
Stanford University Dr. Matthew H Porteus Late Stage Preclinical Projects Genome Editing of Autologous Hematopoietic Stem Cells to Treat Sickle Cell Disease $4,849,363
Cellerant Therapeutics, Inc. Swapna Panuganti Late Stage Preclinical Projects Development of CLT030-ADC, a Leukemic Stem Cell Targeting Antibody-Drug-Conjugate, for Treatment of Acute Myeloid Leukemia $6,863,755
Cellular Biomedicine Group, Inc. Jack J. Wang Late Stage Preclinical Projects Allogenic human adipose-derived mesenchymal stem cells for the treatment of knee osteoarthritis $1,200,000
Stanford University Dr. Gary Steinberg Late Stage Preclinical Projects Intraparenchymal NR1 Stem Cell Therapy for Chronic Subcortical Ischemic Stroke $5,300,000
University of California, San Diego Dr. Stephanie Cherqui Late Stage Preclinical Projects Ex vivo transduced autologous human CD34+ hematopoietic stem cells for treatment of cystinosis $5,273,189
University of California, Los Angeles Dr. Sophie X Deng Late Stage Preclinical Projects Regeneration of a Normal Corneal Surface by Limbal Stem Cell Therapy $4,244,211
ViaCyte, Inc. Dr. Tim Kieffer Late Stage Preclinical Projects Stem cell-derived islet cell replacement therapy with immunosuppression for high-risk type 1 diabetes $3,544,721
University of California, San Francisco Dr Jennifer M Puck Late Stage Preclinical Projects Ex Vivo Transduction of the Human Artemis (DCLRE1C) cDNA by Lentiviral Vector AProArt into CD34+ Hematopoietic Cells for Artemis (ART)-Deficient Severe Combined Immunodeficiency (SCID) $4,268,865
Angiocrine Bioscience, Inc. Dr. Paul W Finnegan Late Stage Preclinical Projects Development of AB-110: genetically-modified endothelial cells plus expanded cord blood hematopoietic stem cells as a transplantation therapy $3,797,117
Calibr Peter G Schultz Late Stage Preclinical Projects Development of a Chondrogenic Drug Candidate Targeting Resident Mesenchymal Stem Cells for the Treatment of Osteoarthritis $1,667,832
Cedars-Sinai Medical Center Shaomei Wang Late Stage Preclinical Projects IND-enabling study of subretinal delivery of human neural progenitor cells for the treatment of retinitis pigmentosa $4,954,514
1 … 18 19 20 21 22 23 24 25 26 27 28 29